Table 2.
Summary of reported cases treated with TKIs as second-line therapy after ICIs
| 1L ICI | N (%) | 2L TKI | N (%) mPFS, months | mOS, months | Toxicity, n (%) | |
|---|---|---|---|---|---|---|
| Auvry et al. [14] (n = 33) | ||||||
| PD-1+CTLA-4 blockade | 33 (100) | All | 8 | − | G3 and G4 AEs | |
| (followed by maintenance anti-PD-1) | Sunitinib | 17 (52) 8 | 11 | 14 (42) | ||
| Pazopanib | 6 (18) | |||||
| Axitinib | 8 (24) 7 | NR | ||||
| Cabozantinib | 2 (6) | |||||
| Other | 5 | 13 | ||||
| Shah et al. [15] (n = 70) | Discontinuation of 2L TKI due to its toxicity | |||||
| Anti-PD-(L)1 single agent | 12 (17) | All | 13.2 | NR | 12 (17) | |
| PD-1+CTLA-4 blockade (followed by maintenance anti-PD-1) | 33 (47) | Sunitinib | 6 (9) | 1 (17) | ||
| PD-(L)1+ anti-VEGF therapy | 25 (36) | Pazopanib | 19 (27) | 8 (42) | ||
| Axitinib | 25 (36) | 3 (12) | ||||
| Cabozantinib | 20 (28) | 0 (0) | ||||
1L, first line; 2L, second line; CTLA-4, cytotoxic T lymphocyte-associated protein 4; ICI, immune checkpoint inhibitors; mOS, median overall survival; mPFS, median progression-free survival; PD-1, programmed death-1; PD-L1, programmed death ligand-1; VEGF, vascular endothelial growth factor TKI, tyrosine kinase inhibitor.